Bone-Targeted Nanozyme Suppresses Breast Cancer Metastases in Mouse Models
Published in Drugs development & discovery, Journals, Nanomedicine.
Published October 25, 2026.
Researchers reporting in Advanced Materials have developed an experimental nanozyme designed to disrupt breast cancer growth in bone while limiting bone destruction. The material, called SPMMPA, was evaluated in mouse models of breast cancer bone metastasis.
The particles combine a Prussian blue core, a porous silica layer and a manganese oxide shell, with surface components intended to target bone. Their catalytic activity increases under acidic conditions, generating reactive oxygen species and depleting glutathione.
The authors report mitochondrial dysfunction and reduced oxidative phosphorylation and ATP production, consistent with interference in tumor energy metabolism. Released silicon and alendronate also contributed to reduced activity of bone-resorbing osteoclasts. Near-infrared light enhanced treatment effects through heating.
In the mouse experiments, the platform suppressed tumor growth and reduced osteolysis. No overt toxicity was detected in the assays performed, which does not establish comprehensive or long-term safety.
These are preclinical findings. The study does not demonstrate safety or efficacy in patients, and clinical translation would require further evaluation of dosing, biodistribution, clearance and potential adverse effects.